A new research paper was published in Oncotarget's Volume 14 on December 20, 2023, entitled, "The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies."
GFH009: Potent, Selective CDK9 Inhibitor for Hematologic Cancer miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Verastem Oncology (VSTM) Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
NEW YORK, June 29, 2022 /PRNewswire/ M.S.Q. Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd.("BioLineRx") (NASDAQ/TASE: BLRX), has successfully entered into a co-development agreement with GenFleet Therapeutics, Inc., an immuno-oncology focused biopharmaceutical company based in Shanghai, China, for the development of Motixafortide in pancreatic ductal adenocarcinoma ("PDAC"). Under the terms of the agreement, GenFleet will design and execute a randomized Phase 2b clinical trial that will enroll approximately 200 first-line metastatic PDAC patients in China. This randomized controlled study will aim to evaluate the superiority of Motixafortide in combination with an anti-PD-1 and chemotherapy compared to chemotherapy alone, the current standard of care. "This collaboration is based on the highly encouraging results from our Phase 2a COMBAT/KEYNOTE-202 study of Motixafortide in combination with an anti-PD-1 and chemotherapy, which provide strong support for continued development in this very challenging disease. With its broad solid tumor oncology pipeline and highly experienced development team, we believe we have found an outstanding partner in GenFleet to execute a rigorously designed randomized Phase 2b trial," said Philip Serlin, CEO of BioLineRx."The MSQ team helped to navigate through the complexity of cross-border transactions and secured this transaction by deploying their deep knowledge of the global market. We are highly impressed with MSQ's "thinking outside the box" approach and their expertise in deal structuring and negotiation." "The results of the COMBAT/KEYNOTE-202 Phase 2a study demonstrate the benefit of combining the CXCR4 inhibitor Motixafortide with an anti-PD-1 and chemotherapy in a second-line setting," said Qiang Lu, Chairman of GenFleet. "We believe that this combination could be beneficial to patients in a first-line setting as well, and we hope to confirm this in a randomized trial. We are thrilled to be partners with BioLineRx in the development of this late-stage clinical asset, and look forward to initiating this important trial as quickly as possible. Throughout this journey, MSQ team has demonstrated professionalism and dedication in helping both of our teams to reach the finish line in a timely fashion." Echo Hindle-Yang, CEO of MSQ, reflects on the transaction, "This collaboration demonstrates another excellent example of global co-development, which leverages each company's regional expertise to accelerate the development of new treatments. We are excited to see the alliance between BioLineRx and Genfleet to pursue the treatment of PDAC, which has proven to be incredibly challenging. I am impressed by Phil's commitment to developing Motixafortide in PDAC which is also shared by GenFleet's Dr. Lu. With such a strong commitment from each team, we believe that patients will benefit from this collaboration. We are honored to move forward with this cross-border partnership, and help achieve future success. About MSQ M.S.Q. Ventures is aNew York-basedcross-border advisoryfirm that bridges thehealthcareindustries globally by offering our deep knowledge, strong network, and local insights into theChinamarket. info@msqventures.com SOURCE MSQ Ventures
NEW YORK, June 29, 2022 /PRNewswire/ M.S.Q. Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd.("BioLineRx") (NASDAQ/TASE: BLRX), has successfully entered into a co-development agreement with GenFleet Therapeutics, Inc., an immuno-oncology focused biopharmaceutical company based in Shanghai, China, for the development of Motixafortide in pancreatic ductal adenocarcinoma ("PDAC"). Under the terms of the agreement, GenFleet will design and execute a randomized Phase 2b clinical trial that will enroll approximately 200 first-line metastatic PDAC patients in China. This randomized controlled study will aim to evaluate the superiority of Motixafortide in combination with an anti-PD-1 and chemotherapy compared to chemotherapy alone, the current standard of care. "This collaboration is based on the highly encouraging results from our Phase 2a COMBAT/KEYNOTE-202 study of Motixafortide in combination with an anti-PD-1 and chemotherapy, which provide strong support for continued development in this very challenging disease. With its broad solid tumor oncology pipeline and highly experienced development team, we believe we have found an outstanding partner in GenFleet to execute a rigorously designed randomized Phase 2b trial," said Philip Serlin, CEO of BioLineRx."The MSQ team helped to navigate through the complexity of cross-border transactions and secured this transaction by deploying their deep knowledge of the global market. We are highly impressed with MSQ's "thinking outside the box" approach and their expertise in deal structuring and negotiation." "The results of the COMBAT/KEYNOTE-202 Phase 2a study demonstrate the benefit of combining the CXCR4 inhibitor Motixafortide with an anti-PD-1 and chemotherapy in a second-line setting," said Qiang Lu, Chairman of GenFleet. "We believe that this combination could be beneficial to patients in a first-line setting as well, and we hope to confirm this in a randomized trial. We are thrilled to be partners with BioLineRx in the development of this late-stage clinical asset, and look forward to initiating this important trial as quickly as possible. Throughout this journey, MSQ team has demonstrated professionalism and dedication in helping both of our teams to reach the finish line in a timely fashion." Echo Hindle-Yang, CEO of MSQ, reflects on the transaction, "This collaboration demonstrates another excellent example of global co-development, which leverages each company's regional expertise to accelerate the development of new treatments. We are excited to see the alliance between BioLineRx and Genfleet to pursue the treatment of PDAC, which has proven to be incredibly challenging. I am impressed by Phil's commitment to developing Motixafortide in PDAC which is also shared by GenFleet's Dr. Lu. With such a strong commitment from each team, we believe that patients will benefit from this collaboration. We are honored to move forward with this cross-border partnership, and help achieve future success. About MSQ M.S.Q. Ventures is aNew York-basedcross-border advisoryfirm that bridges thehealthcareindustries globally by offering our deep knowledge, strong network, and local insights into theChinamarket. info@msqventures.com SOURCE MSQ Ventures
- GenFleet to design and execute randomized Phase 2b triple combination trial of Motixafortide in first-line metastatic PDAC patients in China - - BioLineRx to retain global rights to Motixafortide. | June 28, 2022
GenFleet Therapeutics and Insilico Medicine Announce Strategic Partnership prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.